These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31656151)

  • 1. Inhibitors of Cholinesterases in Pharmacology: the Current Trends.
    Pohanka M
    Mini Rev Med Chem; 2020; 20(15):1532-1542. PubMed ID: 31656151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterases, a target of pharmacology and toxicology.
    Pohanka M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Sep; 155(3):219-29. PubMed ID: 22286807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Influencing of The Cholinergic Anti-inflammatory Pathway in Infectious Diseases and Inflammatory Pathologies.
    Pohanka M
    Mini Rev Med Chem; 2021; 21(6):660-669. PubMed ID: 33208075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coumarins as cholinesterase inhibitors: A review.
    de Souza LG; Rennã MN; Figueroa-Villar JD
    Chem Biol Interact; 2016 Jul; 254():11-23. PubMed ID: 27174134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
    Sharma P; Tripathi MK; Shrivastava SK
    Methods Mol Biol; 2020; 2089():257-286. PubMed ID: 31773661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies.
    Darreh-Shori T; Soininen H
    Curr Alzheimer Res; 2010 Feb; 7(1):67-73. PubMed ID: 20205672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferulic acid and Alzheimer's disease: promises and pitfalls.
    Nabavi SF; Devi KP; Malar DS; Sureda A; Daglia M; Nabavi SM
    Mini Rev Med Chem; 2015; 15(9):776-88. PubMed ID: 26002710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylcholinesterase inhibitors: a patent review (2008 - present).
    Pohanka M
    Expert Opin Ther Pat; 2012 Aug; 22(8):871-86. PubMed ID: 22768972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
    Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
    Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
    Macdonald IR; Rockwood K; Martin E; Darvesh S
    J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors.
    Panek D; Wichur T; Godyń J; Pasieka A; Malawska B
    Future Med Chem; 2017 Oct; 9(15):1835-1854. PubMed ID: 28925729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterase inhibitors and beyond.
    Pepeu G; Giovannini MG
    Curr Alzheimer Res; 2009 Apr; 6(2):86-96. PubMed ID: 19355843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow-binding inhibition of cholinesterases, pharmacological and toxicological relevance.
    Masson P; Lushchekina SV
    Arch Biochem Biophys; 2016 Mar; 593():60-8. PubMed ID: 26874196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the pharmacology of galantamine.
    Villarroya M; García AG; Marco-Contelles J; López MG
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory mechanisms and clinical applications of anticholinesterases.
    Whittaker VP
    Biochem Soc Trans; 1994 Aug; 22(3):729-35. PubMed ID: 7821674
    [No Abstract]   [Full Text] [Related]  

  • 18. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
    Kabir MT; Uddin MS; Begum MM; Thangapandiyan S; Rahman MS; Aleya L; Mathew B; Ahmed M; Barreto GE; Ashraf GM
    Curr Pharm Des; 2019; 25(33):3519-3535. PubMed ID: 31593530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease.
    Li Q; He S; Chen Y; Feng F; Qu W; Sun H
    Eur J Med Chem; 2018 Oct; 158():463-477. PubMed ID: 30243151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.
    Darvesh S; Walsh R; Kumar R; Caines A; Roberts S; Magee D; Rockwood K; Martin E
    Alzheimer Dis Assoc Disord; 2003; 17(2):117-26. PubMed ID: 12794390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.